دورية أكاديمية
أعرض في EDS

Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway.

التفاصيل البيبلوغرافية
العنوان: Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway.
المؤلفون: Chen Y; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China., Bao S; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China., Wang Z; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China., Fang Z; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. fzcz@163.com., Tang H; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. tanghao_0921@126.com.
المصدر: European journal of medical research [Eur J Med Res] 2024 Jul 26; Vol. 29 (1), pp. 387. Date of Electronic Publication: 2024 Jul 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 9517857 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-783X (Electronic) Linking ISSN: 09492321 NLM ISO Abbreviation: Eur J Med Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 2012- : London : BioMed Central
Original Publication: Munich, Germany : I. Holzapfel, c1995-
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/metabolism , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Cisplatin*/pharmacology , NF-E2-Related Factor 2*/metabolism , NF-E2-Related Factor 2*/genetics , Kelch-Like ECH-Associated Protein 1*/metabolism , Kelch-Like ECH-Associated Protein 1*/genetics , Flavonoids*/pharmacology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/metabolism , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Heme Oxygenase-1*/metabolism , Heme Oxygenase-1*/genetics , Macrophages*/drug effects , Macrophages*/metabolism , Macrophages*/immunology, Humans ; Animals ; Mice ; Ferritins/metabolism ; Antineoplastic Agents/pharmacology ; Autophagy/drug effects ; Drug Resistance, Neoplasm/drug effects ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays ; A549 Cells
مستخلص: Background: Cisplatin (DDP) chemotherapy is commonly used in therapy for non-small cell lung cancer (NSCLC), but increased drug resistance has become a huge obstacle. Baicalin (BA) contributed to the sensitivity of NSCLC to DDP. Here, we aimed to further probe the pathophysiological mechanisms of BA in NSCLC.
Methods: A549 and A549/DDP cells and xenograft mice were treated with BA and DDP. Xenograft mice were treated additionally with the NRF2 inducer (Bardoxolone methyl, BM) and KEAP1 knockdown. The levels of ferritinophagy-related proteins and biomarkers were determined. The autophagosomes were observed. M1 macrophage polarization and the contents of related indicators were analyzed. The involvement of KEAP1/NRF2/HO-1 was determined.
Results: BA inhibited cell development, and the effect of BA and DDP on cell development was additive. The abundance of ferritinophagy-related proteins and the number of autophagosomes were induced by BA. BA also promoted the transition of GSH to GSSH. BA favored M1 macrophage polarization and affected the expression of related proteins. When BA and DDP combined, these molecular phenomena were further exacerbated. BA induced accumulation of KEAP1 and reduction of NRF2 and HO-1. However, BM and KEAP1 knockdown disrupted the synergistic effects of BA and DDP on inhibiting NSCLC growth. BM and KEAP1 knockdown reversed DDP and BA-promoted protein expression activity and M1 macrophage polarization.
Conclusion: Our findings suggest that BA is involved in ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 axis, thereby improving the DDP sensitivity in NSCLC, which could provide new candidates for treatment strategies.
(© 2024. The Author(s).)
References: Oxid Med Cell Longev. 2019 Jun 10;2019:3150145. (PMID: 31281572)
Front Plant Sci. 2022 Mar 03;13:866282. (PMID: 35310641)
Mol Cell Biol. 2020 Jun 15;40(13):. (PMID: 32284348)
Cell. 2017 Oct 19;171(3):696-709.e23. (PMID: 28965760)
BMC Cancer. 2010 Mar 25;10:112. (PMID: 20338029)
Autophagy. 2021 Nov;17(11):3361-3374. (PMID: 33404288)
Sci Rep. 2017 Sep 14;7(1):11551. (PMID: 28912423)
Cancer Med. 2020 Jul;9(13):4540-4549. (PMID: 32364685)
Oxid Med Cell Longev. 2016;2016:1958174. (PMID: 26697129)
Biomolecules. 2019 Dec 27;10(1):. (PMID: 31892257)
Int J Mol Sci. 2021 Jun 29;22(13):. (PMID: 34209703)
Med Sci Monit. 2018 Apr 10;24:2126-2133. (PMID: 29632297)
Int J Environ Res Public Health. 2021 May 14;18(10):. (PMID: 34069141)
Nat Rev Drug Discov. 2013 Dec;12(12):931-47. (PMID: 24287781)
Int J Mol Sci. 2020 Jul 11;21(14):. (PMID: 32664576)
Pharmacol Res. 2021 Feb;164:105387. (PMID: 33352232)
Cancers (Basel). 2020 Dec 26;13(1):. (PMID: 33375248)
Acta Pharmacol Sin. 2020 May;41(5):612-619. (PMID: 31796867)
Expert Opin Ther Targets. 2019 Mar;23(3):241-250. (PMID: 30556750)
Phytomedicine. 2021 Jan;80:153370. (PMID: 33113504)
Aging (Albany NY). 2020 Jun 29;12(13):12943-12959. (PMID: 32601262)
Cancer Treat Rev. 2016 Mar;44:42-50. (PMID: 26866673)
Autophagy. 2021 Sep;17(9):2054-2081. (PMID: 32804006)
Pharm Biol. 2018 Dec;56(1):465-484. (PMID: 31070530)
Biomed Pharmacother. 2021 Nov;143:112105. (PMID: 34560533)
Nat Rev Immunol. 2008 Dec;8(12):958-69. (PMID: 19029990)
Front Pharmacol. 2022 Feb 09;12:821485. (PMID: 35222014)
Oxid Med Cell Longev. 2022 Feb 21;2022:3920664. (PMID: 35237380)
Oxid Med Cell Longev. 2022 Apr 16;2022:4505513. (PMID: 35480867)
Oncotarget. 2017 Aug 3;8(42):72544-72563. (PMID: 29069808)
Front Pharmacol. 2018 Sep 04;9:911. (PMID: 30233360)
J Transl Med. 2021 Mar 2;19(1):96. (PMID: 33653364)
Cell Chem Biol. 2020 Apr 16;27(4):436-447. (PMID: 32275864)
Biomed Pharmacother. 2019 Jan;109:2252-2261. (PMID: 30551482)
Mol Cancer. 2020 Sep 11;19(1):141. (PMID: 32917214)
Int J Oncol. 2017 Jan;50(1):93-100. (PMID: 27878245)
Biomed Pharmacother. 2021 Sep;141:111872. (PMID: 34246187)
Sci Rep. 2017 Sep 7;7(1):10760. (PMID: 28883517)
Expert Opin Drug Deliv. 2019 Mar;16(3):301-312. (PMID: 30773947)
Cell Cycle. 2017 Jun 3;16(11):1053-1062. (PMID: 28402166)
Cell Death Dis. 2019 Oct 28;10(11):822. (PMID: 31659150)
Drug Des Devel Ther. 2021 Jan 06;15:21-35. (PMID: 33442234)
Cancers (Basel). 2021 Jan 22;13(3):. (PMID: 33499040)
Eur J Pharmacol. 2010 Mar 25;630(1-3):121-30. (PMID: 20036231)
Int J Mol Sci. 2020 Aug 31;21(17):. (PMID: 32878298)
Cell Mol Biol Lett. 2022 Sep 30;27(1):81. (PMID: 36180832)
Int J Mol Sci. 2021 Aug 12;22(16):. (PMID: 34445366)
Cell Chem Biol. 2020 Apr 16;27(4):420-435. (PMID: 32160513)
Bioengineered. 2021 Dec;12(1):8347-8357. (PMID: 34592879)
Redox Biol. 2019 May;23:101107. (PMID: 30692038)
Phytomedicine. 2022 Nov;106:154411. (PMID: 36030746)
Cell. 2012 May 25;149(5):1060-72. (PMID: 22632970)
معلومات مُعتمدة: 20SG38 "Shuguang Program" supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission; 20XD1423300 Shanghai Municipal Science and Technology Committee of Shanghai outstanding academic leaders plan; 82070036 General Program of National Nature Science Foundation of China
فهرسة مساهمة: Keywords: Baicalin (BA); Cisplatin (DDP); KEAP1-NRF2/HO-1; Non-small cell lung cancer (NSCLC)
المشرفين على المادة: 347Q89U4M5 (baicalin)
Q20Q21Q62J (Cisplatin)
0 (NF-E2-Related Factor 2)
0 (Kelch-Like ECH-Associated Protein 1)
0 (Flavonoids)
EC 1.14.14.18 (Heme Oxygenase-1)
0 (KEAP1 protein, human)
0 (NFE2L2 protein, human)
9007-73-2 (Ferritins)
0 (Antineoplastic Agents)
EC 1.14.14.18 (HMOX1 protein, human)
تواريخ الأحداث: Date Created: 20240726 Date Completed: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11282607
DOI: 10.1186/s40001-024-01930-4
PMID: 39061086
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-783X
DOI:10.1186/s40001-024-01930-4